The high-dose aldesleukin (IL-2) "select" Trial: A trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinoma

Clinical Genitourinary Cancer

Volumn 7, Issue 2, 2009, Pages

  Clement, Jessica ^a   McDermott, David ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Carbonic anhydrase IX (CAIX); Interferon

Indexed keywords

CARBONATE DEHYDRATASE IX; RECOMBINANT INTERLEUKIN 2;

ANURIA; CLINICAL TRIAL; CONFUSION; DOSE RESPONSE; DRUG MEGADOSE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; INFECTION; KIDNEY CARCINOMA; METABOLIC ACIDOSIS; METASTASIS; MODEL; MULTIPLE CYCLE TREATMENT; MYOCARDITIS; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; RESPIRATORY DISTRESS; REVIEW; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT;

EID: 70449378635     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2009.n.014     Document Type: Article

References (31)

1. Linehan WM, Shipley WU, Parkinson DR. Cancer of the kidney and ureter. In: DeVita VT, Jr, ed. Cancer: Principles and Practice of Oncology. 4th ed. Philadelphia: J. B. Lippincott Company; 1993.
2. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996; 335:865.
3. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17:2530.
4. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trails of new therapies against advanced renal cell carcinoma. J CliOncol 2002; 20:289-296
5. Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol Clin North Am 1993; 20:303-314
6. Pyrhonen S, Salminen E, Lehtonen T, et al. Recombinant interferon alfa-2a with vinblastine vs. vinblastine alone in advanced renal cell carcinoma: a phase II study. Proc Am Soc Clin Oncol 1996; 15:244.
7. Muss HB. Interferon therapy for renal cell carcinoma. Semin Oncol 1987; 14:36-42.
8. Muss HB, Costanzi JJ, Leavitt R, et al. Recombinant alfa interferon in renal cell carcinoma: a randomized trial of two routes of administration. J Clin Oncol 1987; 5:286-291
9. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295:2516-2524
10. Motzer RJ, Rini BI, Michaelson MD, et al. SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second line therapy for patients with metastatic renal cell carcinoma: results of a phase II study. J Clin Oncol 2004; 23(suppl):381 (Abstract 4500).
11. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356:115-124
12. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma. N Engl J Med 2007; 356:2271-2281
13. Escudier B, Eisen Stadler TW. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 256:125-134
14. Szczylik C, Demkow T, Staehler M, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. J Clin Oncol 2007; 25(18 suppl):241s (Abstract 5025).
15. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995; 13:688-696
16. Dutcher J. Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma. Oncology 2002; 16:4.
17. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of highdose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23:133-141
18. Besana C, Borri A, Bucci E, et al. Treatment of advanced renal cell cancer with sequential intravenous recombinant interleukin-2 and subcutaneous a-interferon. Eur J Cancer 1994; 9:1292-1298
19. Rosenberg SA, Lotze MT, Yang JC, et al. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989; 7:1863.
20. Figlin R, Gitlitz B, Franklin J, et al. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: An analysis of 203 consecutively treated patients. Cancer J Sci Am 1997; 3:S92.
21. Leibovich BC, Han KR, Bui MH, et al. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 2003; 98:2566-2575
22. Royal RE, Steinberg SM, Krouse RS, et al. Correlates of Response to IL-2 Therapy in Patients Treated for Metastatic Renal Cancer and Melanoma. Cancer J Sci Am 1996; 2:91.
23. Atkins MB, Mier JW, Parkinson DR, et al. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med 1988; 318:1557-1563
24. Fumagalli LA, Vinke J, Hoff W, et al. Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy. J Immunother 2003; 26:394-402.
25. West WH, Tauer KW, Yanelli JR, et al. Constant-infusion recombinant interleukin- 2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987; 316:898-905.
26. Janik JE, Sznol M, Urba WJ, et al. Erythropoietin production. A potential marker for interleukin-2/interferon-responsive tumors. Cancer 1993; 72:2656-2659
27. Cangiano T, Liao J, Naitoh J, et al. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy. J Clin Oncol 1999; 17:523.
28. Motzer RJ, Bacil J, Mariani T, et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002; 20:2376.
29. Upton MP, Parker RA, Youmans A, et al. Renal Cell Carcinoma: Histologic Predictors of Cytokine Response. J Immunother 2005; 28:488-495
30. Bui MH, Seligson D, Han K, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003; 9:802-811
31. Atkins M, Regan M, McDermott D, et al. Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin-2 Therapy for Renal Cancer. Clin Cancer Res 2005; 11:3714-3721